Free Trial
NASDAQ:MTSR

Metsera 3/26/2025 Earnings Report

Metsera logo
$25.65 +2.29 (+9.80%)
As of 05/2/2025 04:00 PM Eastern

Metsera EPS Results

Actual EPS
-$3.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Metsera Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Metsera Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Metsera Earnings Headlines

Metsera Inc. appoints new director and legal officer
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Bank of America Securities Remains a Buy on Metsera, Inc. (MTSR)
Metsera reports Q4 EPS ($3.52) vs. (94c) last year
See More Metsera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metsera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metsera and other key companies, straight to your email.

About Metsera

Metsera (NASDAQ:MTSR) is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

View Metsera Profile

More Earnings Resources from MarketBeat